PDX Resource

By leveraging the wealth of information that we have on each tumor model, we can help you with your study and provide suggested patient-derived xenograft (PDX models) to test. We currently have more than 450 fully characterized proprietary patient-derived xenografts in our portfolio, which represent all major histotypes and tumors, and provide extensive background and characterization. Our PDX Model portfolio includes:

  • Subcutaneous, orthotopic , and disseminated models of cancer
  • Extensive molecular and pharmacological characterization, and complete records on patientsā€˜ pretreatment
  • Integrated approach using the same PDX models and/or the corresponding cell line
  • Integrated approach using the same PDX models and/or the corresponding cell line
  • 2D / 3D screening assays and subsequent PDX in vivo efficacy studies
  • Identification of biomarkers, which predicts tumor sensitivity of compounds
  • PDX Model platform using humanized mice in standard or single mouse trial format (SMT)
Constant addition of new PDX models, which are continuously established through international collaborations with major hospitals and universities. ... Read more

Cancer by System

Data Available